| Literature DB >> 31208056 |
Mamdouh N Samy1, Géraldine Le Goff2, Philippe Lopes3, Katerina Georgousaki4, Sentiljana Gumeni5, Celso Almeida6, Ignacio González7, Olga Genilloud8, Ioannis Trougakos9, Nikolas Fokialakis10, Jamal Ouazzani11.
Abstract
The strain Streptomyces osmaniensis CA-244599 isolated from the Comoros islands was submitted to liquid-state fermentation coupled to in situ solid-phase extraction with amberlite XAD-16 resin. Elution of the trapped compounds on the resin beads by ethyl acetate afforded seven metabolites, osmanicin (1), streptazolin (2), streptazone C (3), streptazone B1 (4), streptenol C (5), nocardamine (6) and desmethylenylnocardamine (7). Osmanicin (1) is a newly reported unusual scaffold combining streptazolin (2) and streptazone C (3) through a Diels-Alder type reaction. Experimental evidence excluded the spontaneous formation of 1 from 2 and 3. The isolated compounds were evaluated for their ability to inhibit elastase using normal human diploid fibroblasts. Compound 1 exhibited the most potent activity with an IC50 of 3.7 μM.Entities:
Keywords: Streptomyces osmaniensis; alkaloids; elastase inhibition; in situ solid-phase extraction; osmanicin
Mesh:
Substances:
Year: 2019 PMID: 31208056 PMCID: PMC6630352 DOI: 10.3390/molecules24122239
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Phylogenetic analysis of Actinomycete isolate CA-244599.
Figure 2Relative (%) elastase inhibitory activity in normal human BJ fibroblasts after 24 h of treatment with shown extracts at the concentration of 1 and 10 µg/mL. Values from controls (cells treated without the extract) were set to 100%. Data are presented as mean ± SD (n ≥ 3). The statistical differences observed in the graphic are significant when compared to control samples, * p < 0.05.
Figure 3Compounds isolated from Streptomyces osmaniensis CA-244599.
NMR spectroscopic data (CD3OD) for osmanicin (1).
| Osmanicin (1) a | |||
|---|---|---|---|
| No. | δC, type | δH, mult. ( | HMBC |
| 2 | 43.4, CH2 | 3.62, bt (7.4) | C-3, 4, 19 |
| 3 | 36.2, CH2 | 2.39, (dt (8.4, 3.9) | C-2, 4, 5 |
| 4 | 185.7, C | ||
| 5 | 112.4, C | ||
| 6 | 61.0, C | ||
| 7 | 38.9, CH | 2.81, b quint (7.6) | C-6, 21, 22 |
| 8 | 33.2, CH | 2.60, m | C-6, 23 |
| 9 | 141.3, C | ||
| 10 | 80.0, CH | 4.68, m | C-9, 11 |
| 11 | 83.5, CH | 4.69, m | C-10, 12, 13, 18 |
| 12 | 64.5, CH | 4.53, b d (1.4) | C-18 |
| 13 | 138.7, C | ||
| 14 | 38.8, CH | 3.36, m | C-13, 16 |
| 15 | 28.6, CH2 | 1.02, m | |
| 16 | 43.6, CH2 | 3.11, td (13.3, 3.2) | C-18 |
| 3.58, dd (5.1, 2.3) | |||
| 18 | 160.0, C | ||
| 19 | 169.2, C | ||
| 20 | 127.4, CH | 6.33, d (5.8) | C-5, 6, 19, 21 |
| 21 | 154.6, CH | 6.78, d (5.8) | C-5, 6, 20 |
| 22 | 12.8, CH3 | 1.05, d (7.4) | C-6, 7, 8 |
| 23 | 13.4, CH3 | 0.62, d (7.1) | C-7, 8, 9 |
a 1H and 13C chemical shifts were recorded at 300 and 75 MHz respectively.
Figure 4Key COSY and HMBC correlations for compound 1.
Figure 5Confirmation of the stereochemistry at C-6.
Figure 6The proposed biosynthetic pathway of osmanicin (1).
Figure 7Relative (%) elastase inhibitory activity in human fibroblasts after 24 h of treatment with pure compounds at the concentration 5 μM. Values from controls (cells treated without the extract) were set to 100%. Data are presented as mean ± SD (n = 3). Shown differences are significant vs. control samples, * p < 0.05.
Figure 8Determination of the IC50 inhibitory concentration of osmanicin against elastase (A) and cell survival after osmanicin treatment (B). (A) The half maximal inhibitory concentration (IC50) of osmanicin against elastase was calculated by plotting the graph between the different concentrations used (1 μM to 5 μM) and the % inhibition of elastase activity. Data are presented as mean ± SD (n ≥ 3). (B) Relative (%) survival (MTT assay) of BJ fibroblasts exposed to the indicated concentrations of osmanicin for 24 h. Data are presented as mean ± SD (n ≥ 3).